From complexity to approval in the European Union: Regulatory pathways and data challenges in the evaluation of non-oncology orphan medicines.

Andriantafika G, Janssen H, Balkowiec-Iskra E, Gartner C, Sepodes B, Van der Schueren B

Open source

DOI
10.1016/j.drudis.2026.104715
Published
2026 Jul
Container
Drug discovery today
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.drudis.2026.104715,
  title = {From complexity to approval in the European Union: Regulatory pathways and data challenges in the evaluation of non-oncology orphan medicines.},
  author = {Andriantafika G and Janssen H and Balkowiec-Iskra E and Gartner C and Sepodes B and Van der Schueren B},
  year = {2026},
  journal = {Drug discovery today},
  doi = {10.1016/j.drudis.2026.104715},
  url = {https://doi.org/10.1016/j.drudis.2026.104715}
}

RIS

TY  - JOUR
TI  - From complexity to approval in the European Union: Regulatory pathways and data challenges in the evaluation of non-oncology orphan medicines.
AU  - Andriantafika G
AU  - Janssen H
AU  - Balkowiec-Iskra E
AU  - Gartner C
AU  - Sepodes B
AU  - Van der Schueren B
PY  - 2026
JO  - Drug discovery today
DO  - 10.1016/j.drudis.2026.104715
UR  - https://doi.org/10.1016/j.drudis.2026.104715
ER  - 

APA

G, A., H, J., E, B., C, G., B, S., & B, V. D. S. (2026). From complexity to approval in the European Union: Regulatory pathways and data challenges in the evaluation of non-oncology orphan medicines.. Drug discovery today. https://doi.org/10.1016/j.drudis.2026.104715

Source records